ReleaseWire Connect

The global vascular grafts market is forecast to exhibit a CAGR of 5.0% between 2016 and 2024. Given the pace, the market's valuation will be US$3.29 bn by the end of 2024, from US$2.15 bn in 2015. Among the key end users, the dominance is forecast to remain with hospitals, which also constituted the leading share of 41.8% in the market in 2016. Regionally, holding over 45% of the global vascular grafts market, North America emerged dominant in the same year.

Analysts have pegged the global pharmerging market to expand at a highly optimistic CAGR of 11.30% within a forecast period from 2016 to 2024, owing to several drivers such as the increasing demand for pharma products overall. The market is expected to reach US$1.40 bn by the end of 2024, after being evaluated at US$552.80 mn in 2015.

According to a TMR analyst, "The global market for peptide therapeutics was pegged at US$21.3 bn in 2015 and is expected to rise to a valuation of US$46.6 bn by 2024. The market is expected to expand at a 9.10% CAGR from 2016 to 2024."

According to TMR, the world patient warming devices market has been prophesied to earn an around US$2.78 bn by 2024. This revenue valuation could progress at a CAGR of 5.3% during the forecast period 2016–2024 from a US$1.73 bn touched in 2015. By product, surface warming system has been envisaged to attain a maximum share by the concluding forecast year as it had secured an approximate 76.0% in 2015. In respect of geography, forecasted to be trailed by Europe at close quarters in future, North America could continue its dominance in the market, evident by its 45.7% share in 2015.

The global market for cervical dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for over 76% of the overall market in 2015, observes a recent report by Transparency Market Research. These top vendors, namely Qiagen AG, Hologic Inc., and F. Hoffmann-La Roche Ltd, have strengthened their hold on the market owing to strategies such as collaboration with leading pharmaceutical and biotechnology companies and successful and focused R&D activities.

The global glaucoma therapeutics market is immensely consolidated and the top five players accounted for just under 85.0% of the market in 2015. Among Novartis AG, Allergan plc., Pfizer Inc., Merck & Co., and Santen Pharmaceuticals, Novartis is the clear leader with a massive share of over 33.0%.

The global market for advanced wound care management, being a highly technology- and research- oriented specialty sector of the overall wound care market, features few companies and a highly consolidated competitive landscape, observes a recent report by Transparency Market Research. The top four vendors in the market, namely Molnlycke Health Care, Smith and Nephew plc, Convatec, and Acelity L.P. Inc., accounted for a share of nearly 65% of the global market in 2015. The market is highly competitive in terms of product pricing and the rate of introduction of new product varieties.

The global market for bovine respiratory disease treatment features a highly consolidated competitive landscape despite the presence of a large number of regional players, observes a recent report by Transparency Market Research. Owing to the small duration of product exclusivity in the animal health care industry – about three to five years - competition from generics and over-the-counter (OTC) products is a big threat.

The global orthopedic braces and support, casting, and splints market is highly fragmented and is marked by the presence of a large number of international as well as local players. Distributors around the world are collaborating with small manufacturers to offer off-label products with a high profit margin, notes Transparency Market Research.

Blood cell analyzers are commercially used in laboratory settings for characterizing various components of blood, notably complete blood count and differential counts, for the detection of various blood-related disorders and several common physiological indications. The wide application of blood analysis for diagnosing indications such as anemia, diabetes, autoimmune disorders, and cancer is boosting the evolution of the market. The rapid evolution of automated cell counters that incorporates a large number of analysis parameters into a single instrument platform with the ability to offer rapid results is a notable development catalyzing the growth of the market. In recent years, the market has witnessed the advent of diagnostic point-of-care analyzers that offer reliable precise results, thereby facilitating faster treatment. Advancement in chemical reagents and physical technologies used in blood cell analyzers bodes well for the market.